Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, expanding its immunology pipeline ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Blueprint Medicines stock was soaring Monday after French drugmaker Sanofi said it had agreed to buy the biotech company for ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, ...

SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.

This happened after Sanofi announced plans to buy the company for $9.1 billion in stock value and up to $9.5 billion in ...

Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in ...

A French pharmaceutical giant is acquiring a Cambridge, Mass. biotech and its rare immunology disease treatment which is ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...